Press Releases

April 2, 2003

San Diego, CA - April 2, 2003 – Imagenetix, Inc. (OTC/BB: IAGX) announces the filing of a patent application with the U.S. Patent Office for its Genepril™ bioceutical composition. Imagenetix is seeking claims for the prevention and treatment of various types of arthritis and other inflammatory joint diseases as well as psoriasis, lupus, and cardiovascular conditions. The patent application states that Genepril may be used in humans and canines, is applied topically or taken orally and can be administered effectively once or twice a day.

The Genepril composition may reduce or avoid many of the side effects associated with conventional treatments. The application also notes that the Genepril composition can be used as a sole treatment or in conjunction with other drugs or therapies. The Company is evaluating the licensing of Genepril to an appropriate pharmaceutical partner.

Mr. William P. Spencer, CEO, Imagenetix, stated that Genepril has been the subject of research involving animal and human trials at the University of Minnesota and the University of Connecticut. These studies have produced results supporting a significant efficacy profile. The Genepril composition continues to be the subject of university based research studying its effects on inflammatory conditions and cardiovascular health. Genepril will be the subject of presentations at two international scientific meetings this year.

Burns, Doane, Swecker and Mathis LLP, one of the oldest and largest law firms in the U.S. specializing exclusively in intellectual property matters, filed the patent application.